Cytokinetics(CYTK)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CYTK Cytokinetics

已收盘 10-28 16:00:00 EDT

61.28

-0.24

-0.39%

盘后60.59

-0.69-1.13%

19:30 EDT

最高61.39	最低60.15	成交量127.42万
今开60.86	昨收61.52	日振幅2.02%
总市值85.19亿	流通市值84.58亿	总股本1.39亿
成交额7,752万	换手率0.92%	流通股本1.38亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CYTK","market":"US","secType":"STK","nameCN":"Cytokinetics","latestPrice":61.28,"timestamp":1793217600000,"preClose":61.52,"halted":0,"volume":1274169,"hourTrading":{"tag":"盘后","latestPrice":60.58841,"preClose":61.28,"latestTime":"19:30 EDT","volume":34671,"amount":2122331.74329,"timestamp":1793230202367,"change":-0.69159,"changeRate":-0.011286,"amplitude":0.011286},"delay":0,"changeRate":-0.0039011703511053638,"floatShares":138019929,"shares":139023418,"eps":-7.182729,"marketStatus":"已收盘","change":-0.24,"latestTime":"10-28 16:00:00 EDT","open":60.86,"high":61.39,"low":60.145,"amount":77518938.44058,"amplitude":0.020237,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-7.182729,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1793260800000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1083211200000,"exchange":"NASDAQ","adjPreClose":61.52,"preHourTrading":{"tag":"盘前","latestPrice":60.56,"preClose":61.52,"latestTime":"09:29 EDT","volume":10766,"amount":659141.965762,"timestamp":1793194190120,"change":-0.96,"changeRate":-0.015605,"amplitude":0.047789},"postHourTrading":{"tag":"盘后","latestPrice":60.58841,"preClose":61.28,"latestTime":"19:30 EDT","volume":34671,"amount":2122331.74329,"timestamp":1793230202367,"change":-0.69159,"changeRate":-0.011286,"amplitude":0.011286},"volumeRatio":1.051475,"impliedVol":0.5227,"impliedVolPercentile":0.3347},"requestUrl":"/m/hq/s/CYTK","defaultTab":"news","newsList":[{"id":"1117169368","title":"财报前瞻 | Cytokinetics本季度营收预计增1058.60%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1117169368","media":"财报Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117169368?lang=zh_cn&edition=full","pubTime":"2026-10-28 10:57","pubTimestamp":1793156249,"startTime":"0","endTime":"0","summary":"Cytokinetics计划于2026年11月04日发布2026财年第三季度业绩，市场关注Myqorzo放量、适应症拓展与费用曲线走向。公司主营以“产品”收入为主体，上一季度“产品”实现2,533.40万美元，占比88.51%，构成清晰、现金化路径明确、与商业化团队的推广节奏一致。面向发展前景最大的现有业务，Myqorzo现阶段以“产品”收入为核心支撑，上季度公司整体营收2,862.40万美元，同比-57.13%，其中“产品”贡献度高，带动收入结构相对集中并为本季度放量预留弹性。机构观点以看多为主。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 | Cytokinetics本季度营收预计增1058.60%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYTK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180887890","title":"异动解读｜Cytokinetics盘中上涨5.1%，ESC大会积极临床数据与适应症拓展预期持续提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1180887890","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180887890?lang=zh_cn&edition=full","pubTime":"2026-09-09 01:43","pubTimestamp":1788889407,"startTime":"0","endTime":"0","summary":"9月9日，Cytokinetics盘中上涨5.1%，报76.43美元/股，成交额8458.42万美元。消息面上，公司近期在欧洲心脏病学会大会最新突破性临床试验专场公布了ACACIA-HCM三期关键试验完整数据，aficamten在非梗阻性肥厚型心肌病患者中成功达到KCCQ-CSS与最大运动能力双主要终点，且未出现新安全信号。公司计划于第四季度向FDA递交补充新药申请，将aficamten适应症拓展至成人非梗阻性HCM群体。此外，公司已宣布参加9月投资者会议，市场对其核心产品Myqorzo商业化放量及适应症扩展前景持续关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Cytokinetics股价上涨，HCM新药数据亮眼","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYTK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167178592","title":"Cytokinetics在2026年欧洲心脏病学会大会最新突破性临床试验专场公布Acacia-HCM与Maple-HCM研究新增结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1167178592","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167178592?lang=zh_cn&edition=full","pubTime":"2026-08-29 22:31","pubTimestamp":1788013912,"startTime":"0","endTime":"0","summary":"Cytokinetics公司于近日宣布，在2026年欧洲心脏病学会大会的“最新突破性临床试验”专场中，正式公布了来自Acacia-HCM及Maple-HCM两项研究的最新数据结果。Cytokinetics此番披露的新增结果，也再次将业界目光汇聚于其在肥厚型心肌病治疗领域的持续深耕。尽管公司官方公告并未展开详述具体数据细节，但能够入选ESC大会的Late Breaking专场，本身便意味着这两项试验在方法学设计、执行质量或初步发现上，已获得了国际专家评审团的高度认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4505","CYTK","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662094713","title":"细胞动力学公司（CYTK）公布肥厚型心肌病药物晚期试验完整数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2662094713","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662094713?lang=zh_cn&edition=full","pubTime":"2026-08-28 23:20","pubTimestamp":1787930438,"startTime":"0","endTime":"0","summary":"按照当前规划，细胞动力学计划在2026年第四季度向FDA递交补充新药申请，推动aficamten适应症拓展至成人非阻塞性肥厚型心肌病群体。若申请顺利获批，该药物适用患者范围将进一步扩大，覆盖更多肥厚型心肌病细分人群。","market":"other","thumbnail":"https://static.szfiu.com/news/20250107/NWE0NDM0MDU5NDk3NzI5.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NWE0NDM0MDU5NDk3NzI5.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305445","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","BK4588","BK4585","CYTK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170159560","title":"异动解读｜Cytokinetics盘中下跌6.03%，三期临床详细数据公布后利好兑现承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1170159560","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170159560?lang=zh_cn&edition=full","pubTime":"2026-08-28 21:32","pubTimestamp":1787923929,"startTime":"0","endTime":"0","summary":"8月28日，Cytokinetics盘中下跌6.03%，报73.37美元/股，成交额1092.93万美元。尽管数据积极，但该试验顶线结果早在5月5日已公布并推动股价单日暴涨逾20%，本次为详细数据的确认性披露，市场呈现典型\"利好兑现\"走势。此外，公司此前一个交易日已下跌1.6%，延续获利回吐压力。公司计划于第四季度向FDA提交补充申请。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"三期临床数据落地，Cytokinetics利好兑现下跌","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYTK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199507806","title":"异动解读｜Cytokinetics盘前上涨6.74%，Acacia-HCM研究成果登刊NEJM并计划Q4提交FDA申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1199507806","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199507806?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:16","pubTimestamp":1787912197,"startTime":"0","endTime":"0","summary":"8月28日，Cytokinetics盘前上涨6.74%，报81.055美元/股，成交额39.26万美元。消息面上，公司Acacia-HCM三期关键临床研究成果在欧洲心脏病学会年会热点专场正式揭晓，并同步发表于顶级医学期刊《新英格兰医学杂志》。与此同时，公司宣布计划于第四季度向美国FDA提交Aficamten的补充新药申请，用于治疗有症状的非梗阻性肥厚型心肌病成人患者。RBC此前预计，若nHCM适应症获批，可为Myqorzo带来约13亿美元的美国增量收入。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Cytokinetics盘前上涨，Acacia-HCM登刊NEJM并拟申请FDA","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYTK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101118898","title":"Cytokinetics盘前股价上扬1.4%，公司于欧洲心脏病学会公布心脏病药物后期临床试验新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1101118898","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101118898?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:12","pubTimestamp":1787911969,"startTime":"0","endTime":"0","summary":"Cytokinetics的股价在盘前交易时段上涨了1.4%。此前，该公司在欧洲心脏病学会上展示了其心脏病治疗药物最新的后期阶段临床试验数据。这一消息无疑为市场注入了新的活力，投资者对这款药物的前景表现出了浓厚的兴趣。盘前股价的积极反应，反映出市场对Cytokinetics研发管线中这一关键产品的乐观情绪。\n值得注意的是，这一涨幅虽然不算剧烈，但在竞争激烈、消息面繁杂的生物科技板块中，仍显得尤为突出。该公司选择在这样一个备受瞩目的国际学术会议上披露数据，也凸显了其对自身研究成果的信心。市场分析师指出，晚期临床数据的成熟与否，往往是决定此类药物能否顺利上市的关键一环。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","CYTK","BK4505","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143836713","title":"Cytokinetics重磅发布：Acacia-HCM临床研究佳绩亮相ESC 2026热点会议，同步登刊《新英格兰医学杂志》","url":"https://stock-news.laohu8.com/highlight/detail?id=1143836713","media":"美股速递","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143836713?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:46","pubTimestamp":1787910377,"startTime":"0","endTime":"0","summary":"Cytokinetics今日宣布，其备受瞩目的Acacia-HCM研究成果在2026年欧洲心脏病学会年会热点专场中正式揭晓，并同步发表于国际顶级医学期刊《新英格兰医学杂志》。业内分析师指出，这一进展不仅巩固了Cytokinetics在心血管精准治疗赛道的领先地位，更可能为全球HCM患者群体带来全新的治疗选择。截至目前，Cytokinetics表示将继续推进该药物的全球注册申请工作，并计划在未来的学术会议中公布更多亚组分析及长期随访数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYTK","BK4505","BK4139","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165592458","title":"Cytokinetics计划于第四季度向美国FDA提交Aficamten补充新药申请，用于治疗有症状的梗阻性肥厚型心肌病成人患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1165592458","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165592458?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:46","pubTimestamp":1787910377,"startTime":"0","endTime":"0","summary":"Cytokinetics宣布，计划在第四季度向美国食品药品监督管理局（FDA）提交Aficamten的补充新药申请。此项申请旨在寻求该药物用于治疗患有症状性非梗阻性肥厚型心肌病（nHCM）的成人患者。这一举措标志着公司在推进这一潜在治疗方案方面迈出了关键一步。值得注意的是，此次提交的适应症聚焦于nHCM患者群体，这与之前的研究方向保持一致。随着第四季度的临近，业界将密切关注这一监管里程碑的进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CYTK","BK4585","BK4588","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153860990","title":"Cytokinetics重磅预告：将亮相2026年欧洲心脏病学会（ESC）大会并发表多项报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1153860990","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153860990?lang=zh_cn&edition=full","pubTime":"2026-08-20 19:31","pubTimestamp":1787225474,"startTime":"0","endTime":"0","summary":"Cytokinetics今日宣布，公司将在2026年欧洲心脏病学会大会上带来一系列备受瞩目的学术报告。这家专注于心血管疾病创新疗法研发的生物制药公司，计划在此次国际顶级医学盛会上展示其最新研究成果与临床进展。Cytokinetics的参与无疑将成为本次大会的一大亮点。随着大会日期的临近，业界对Cytokinetics的表现拭目以待，而这场学术盛宴也势必将为心血管治疗领域注入新的活力与思考。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","CYTK","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659301150","title":"Cytokinetics对百时美施贵宝提起专利侵权诉讼。","url":"https://stock-news.laohu8.com/highlight/detail?id=2659301150","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659301150?lang=zh_cn&edition=full","pubTime":"2026-08-13 21:31","pubTimestamp":1786627862,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0306806265.USD","BK4559","LU0432979614.USD","LU2242652126.USD","IHE","LU1430594728.SGD","LU1868836914.USD","LU2242646821.SGD","CYTK","LU0096364046.USD","IE0009355771.USD","LU0868494617.USD","LU1670711040.USD","LU1074936037.SGD","BK4588","IE00BFXG1179.USD","LU1670710661.SGD","LU1718418525.SGD","LU1868837136.USD","IE00BJT1NW94.SGD","LU0225771236.USD","LU1989771016.USD","LU2596442595.SGD","LU0114720955.EUR","IE0002141913.USD","BK4585","IE00BFTCPJ56.SGD","LU1868836591.USD","IE00BSNM7G36.USD","BK4532","LU0306807586.USD","FTXH","LU2125154778.USD","LU1291159041.SGD","LU0225284248.USD","LU1093756168.USD","LU0456855351.SGD","BK4139","LU0882574055.USD","LU2133065610.SGD","LU0267386448.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU2360032135.SGD","BK4505","LU0061475181.USD","LU1585245621.USD","BMY","LU2125154935.USD","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156890297","title":"Cytokinetics 寻求禁令，阻止针对 Myqorzo（Aficamten）的诉讼或侵权主张 —— SEC 文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1156890297","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156890297?lang=zh_cn&edition=full","pubTime":"2026-08-13 21:28","pubTimestamp":1786627695,"startTime":"0","endTime":"0","summary":"Cytokinetics 已正式向法院寻求禁令，旨在阻止针对其药物 Myqorzo（Aficamten）的潜在诉讼或侵权索赔。这一举措，源自该公司最新提交的 SEC 文件。文件中明确显示，Cytokinetics 正积极采取法律行动，以捍卫其核心资产免受法律纠纷的冲击。此举，无疑凸显了该公司对保护其研发成果的坚定决心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYTK","BK4139","BK4585","BK4505","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160201211","title":"Cytokinetics 宣布 Myqorzo®▼（Aficamten）获英国 MHRA 上市许可，并获 NICE 积极推荐用于英格兰和威尔士症状性梗阻性肥厚型心肌病","url":"https://stock-news.laohu8.com/highlight/detail?id=1160201211","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160201211?lang=zh_cn&edition=full","pubTime":"2026-07-30 18:20","pubTimestamp":1785406832,"startTime":"0","endTime":"0","summary":"Cytokinetics 今日宣布，其旗下药物 Myqorzo▼已获得英国药品和健康产品管理局的上市许可。与此同时，英国国家卫生与临床优化研究所也针对该药物发布了积极指南，支持其在英格兰和威尔士地区用于治疗症状性梗阻性肥厚型心肌病。此次获批与推荐，基于关键的临床研究数据，证明了 Aficamten 在改善患者运动能力、缓解症状以及降低左心室流出道压差方面的显著疗效。对于英格兰和威尔士的患者与医生而言，这无疑提供了一项重要的新治疗选项。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CYTK","BK4585","BK4588","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125697689","title":"英国药品与健康产品管理局：已与Cytokinetics达成保密折扣协议，Aficamten将以更低价格惠及NHS","url":"https://stock-news.laohu8.com/highlight/detail?id=1125697689","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125697689?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:52","pubTimestamp":1785405129,"startTime":"0","endTime":"0","summary":"英国药品与健康产品管理局（Mhra）宣布，已与生物制药公司Cytokinetics（CYTK）达成一项保密折扣协议。根据该协议，药物Aficamten将以降低后的成本，向英国国家医疗服务体系（NHS）提供。此举旨在通过价格调整，让更多患者能负担得起这种治疗药物。Mhra强调，协议的具体折扣金额属于商业机密，不予公开。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","BK4588","CYTK","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116564251","title":"财报前瞻｜Cytokinetics本季度营收预计增529.37%，机构观点偏审慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1116564251","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116564251?lang=zh_cn&edition=full","pubTime":"2026-07-30 11:23","pubTimestamp":1785381804,"startTime":"0","endTime":"0","summary":"Cytokinetics将于2026年08月06日发布财报，市场聚焦营收恢复与费用投放节奏及每股收益的弹性。市场一致预期显示，本季度Cytokinetics营收预计为1,738.18万美元，同比增长629.37%；EBIT预计为-1.94亿美元，同比降幅扩大至74.08%；调整后每股收益预计为-1.64美元，同比降幅扩大至46.47%。综合近期对Cytokinetics的公开分析师评论，观点以审慎为主，看空占比更高。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Cytokinetics本季度营收预计增529.37%，机构观点偏审慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYTK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128861683","title":"Cytokinetics公布三项欧洲心脏病学会2026年会最新突破性科学研究摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=1128861683","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128861683?lang=zh_cn&edition=full","pubTime":"2026-07-07 19:39","pubTimestamp":1783424373,"startTime":"0","endTime":"0","summary":"Cytokinetics公司宣布，将在2026年欧洲心脏病学会年会上展示三项最新突破性科学研究摘要。这一消息标志着该公司在心衰治疗领域的研究进展再次获得国际顶级学术会议的认可。欧洲心脏病学会年会是全球心血管领域规模最大、最具影响力的科学盛会之一，入选其最新突破性科学环节的研究通常代表了该领域的前沿发现与重要临床进展。此次公布的三项摘要内容预计将涉及Cytokinetics在心衰药物开发方面的最新数据与分析。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4588","CYTK","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115149489","title":"异动解读｜Cytokinetics盘中上涨5.17%，报79.1美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1115149489","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115149489?lang=zh_cn&edition=full","pubTime":"2026-06-18 00:25","pubTimestamp":1781713528,"startTime":"0","endTime":"0","summary":"6月17日，Cytokinetics盘中上涨5.17%，报79.1美元/股，成交额8931.1万美元。Cytokinetics所在的生物科技行业中，个股中，uniQure N.V.涨73.69%，艾伯维公司跌0.21%，吉利德科学跌0.3%，安进跌0.25%，Nuvalent, Inc.跌0.0%。Cytokinetics是一家处于临床阶段的生物制药公司，主要致力于发现和开发调节肌肉功能的新型小分子治疗方法，为重大疾病提供潜在治疗方案。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYTK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172862671","title":"Cytokinetics在欧盟推出Myqorzo® (Aficamten)，德国率先实现商业化供应","url":"https://stock-news.laohu8.com/highlight/detail?id=1172862671","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172862671?lang=zh_cn&edition=full","pubTime":"2026-06-01 19:31","pubTimestamp":1780313471,"startTime":"0","endTime":"0","summary":"Cytokinetics公司宣布，其药物Myqorzo® (Aficamten) 现已在欧盟市场正式推出，首站商业供应落地德国。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CYTK","BK4588","BK4505","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157407399","title":"Cytokinetics宣布在德国推出Myqorzo (Aficamten)，用于治疗有症状的梗阻性肥厚型心肌病","url":"https://stock-news.laohu8.com/highlight/detail?id=1157407399","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157407399?lang=zh_cn&edition=full","pubTime":"2026-06-01 19:30","pubTimestamp":1780313418,"startTime":"0","endTime":"0","summary":"Cytokinetics公司宣布，其新药Myqorzo（通用名：Aficamten）现已在德国正式上市，该药物适用于治疗有症状的梗阻性肥厚型心肌病（oHCM）患者。\n这一商业化的推进，标志着该创新疗法在关键欧洲市场迈出了重要一步。Myqorzo是一种口服小分子心肌肌球蛋白抑制剂，旨在通过靶向心肌过度收缩的潜在机制来改善患者的心脏功能并缓解相关症状。其在德国的成功推出，为当地受此疾病困扰的患者提供了一个新的治疗选择。\n","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4588","CYTK","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152068979","title":"异动解读 | Cytokinetics盘中大涨5.64%，公开发行募资完成及关键III期试验达双重终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1152068979","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152068979?lang=zh_cn&edition=full","pubTime":"2026-05-09 00:15","pubTimestamp":1778256939,"startTime":"0","endTime":"0","summary":"Cytokinetics（股票代码：CYTK）今日盘中大涨5.64%，引起了市场的广泛关注。消息面上，公司近期完成了公开发行普通股的交割，此次发行募资总额达8.05亿美元，为公司后续的商业化进程及研发管线的推进提供了坚实的资金保障。此外，公司此前公布的心肌肌球蛋白抑制剂aficamten治疗非梗阻性肥厚型心肌病的关键III期ACACIA-HCM试验，达到了预设的双重主要终点，在临床评估中显示出统计学上的显著改善。值得注意的是，其竞品在同类适应症的试验中未能成功，这使得Cytokinetics在该领域取得了领先优势。这些积极进展增强了投资者对公司未来增长潜力的信心，共同推动了股价的显著上扬。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CYTK"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cytokinetics.com;ir.cytokinetics.com","stockEarnings":[{"period":"1week","weight":-0.038},{"period":"1month","weight":-0.0486},{"period":"3month","weight":-0.2152},{"period":"6month","weight":-0.0383},{"period":"1year","weight":0.0223},{"period":"ytd","weight":-0.0318}],"compareEarnings":[{"period":"1week","weight":0.0008},{"period":"1month","weight":-0.0022},{"period":"3month","weight":0.0551},{"period":"6month","weight":0.071},{"period":"1year","weight":0.1232},{"period":"ytd","weight":0.1287}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Cytokinetics, Incorporated于1997年8月5日成立，符合特拉华州的法律规定。它是一家处于临床阶段的生物制药公司，主要致力于为重大疾病和糟糕的医疗条件提供潜在的治疗方法的这样一种调节肌肉功能的新型小分子治疗方法的发现和发展。它目前处于发展阶段，着重于科研，开发药品筛选技术和融资。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":0.002159},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.023832},{"month":3,"riseRate":0.5,"avgChangeRate":-0.000279},{"month":4,"riseRate":0.590909,"avgChangeRate":0.014515},{"month":5,"riseRate":0.608696,"avgChangeRate":0.027623},{"month":6,"riseRate":0.434783,"avgChangeRate":0.004691},{"month":7,"riseRate":0.652174,"avgChangeRate":0.05362},{"month":8,"riseRate":0.608696,"avgChangeRate":0.035217},{"month":9,"riseRate":0.391304,"avgChangeRate":0.029627},{"month":10,"riseRate":0.304348,"avgChangeRate":-0.070623},{"month":11,"riseRate":0.5,"avgChangeRate":0.021311},{"month":12,"riseRate":0.454545,"avgChangeRate":0.096331}],"exchange":"NASDAQ","name":"Cytokinetics","nameEN":"Cytokinetics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cytokinetics(CYTK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Cytokinetics(CYTK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Cytokinetics,CYTK,Cytokinetics股票,Cytokinetics股票老虎,Cytokinetics股票老虎国际,Cytokinetics行情,Cytokinetics股票行情,Cytokinetics股价,Cytokinetics股市,Cytokinetics股票价格,Cytokinetics股票交易,Cytokinetics股票购买,Cytokinetics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cytokinetics(CYTK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Cytokinetics(CYTK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}